Amylyx Pharmaceuticals Ownership | Who Owns Amylyx Pharmaceuticals?


OverviewForecastFinancialsChartTranscripts

Amylyx Pharmaceuticals Ownership Summary


Amylyx Pharmaceuticals is owned by 122.91% institutional investors, 7.62% insiders. Fmr is the largest institutional shareholder, holding 12.77% of AMLX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.52% of its assets in Amylyx Pharmaceuticals shares.

AMLX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAmylyx Pharmaceuticals122.91%7.62%-30.54%
SectorHealthcare Stocks 42.53%10.81%46.67%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr11.38M12.77%$154.64M
Perceptive advisors8.95M10.04%$121.66M
Blackrock funding, inc. /de7.14M8.01%$97.04M
Adage capital partners gp6.82M7.65%$92.64M
Tcg crossover management6.24M7.00%$84.85M
Vanguard group5.27M5.92%$71.67M
Saturn v capital management4.60M5.17%$62.58M
Commodore capital lp4.08M4.57%$55.39M
Blackrock2.67M3.93%$5.07M
First light asset management3.36M3.76%$45.61M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Saturn v capital management4.60M13.72%$62.58M
Allostery investments lp120.12K9.81%$769.96K
Great point partners1.70M9.53%$23.10M
Almitas capital2.12M6.60%$28.85M
Acuta capital partners333.26K4.68%$4.53M
First light asset management3.36M4.30%$45.61M
Tcg crossover management6.24M4.17%$84.85M
Boxer capital management900.00K3.90%$12.23M
Ally bridge group (ny)437.39K3.62%$5.94M
Perceptive advisors8.95M3.51%$121.66M

Top Buyers

HolderShares% AssetsChange
Fmr11.38M0.01%8.33M
Commodore capital lp4.08M2.70%4.08M
First light asset management3.36M4.30%3.36M
Paradigm biocapital advisors lp1.90M0.73%1.90M
Blackrock funding, inc. /de7.14M0.00%1.63M

Top Sellers

HolderShares% AssetsChange
Nantahala capital management935.68K0.44%-2.00M
Adage capital partners gp6.82M0.15%-1.98M
Franklin resources---1.86M
Blackrock2.67M0.00%-1.80M
Point72 asset management2.79M0.06%-1.75M

New Positions

HolderShares% AssetsChangeValue
Commodore capital lp4.08M2.70%4.08M$55.39M
First light asset management3.36M4.30%3.36M$45.61M
Paradigm biocapital advisors lp1.90M0.73%1.90M$25.82M
Eventide asset management1.51M0.34%1.51M$20.55M
Logos global management lp1.45M1.77%1.45M$19.71M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-10.00
Kelly financial services-33.00
Skopos labs-42.00
Raymond james financial-104.00
Fernwood investment management-200.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202517034.92%109,563,43439.61%1221.59%10146.38%4643.75%
Jun 30, 2025131-2.96%81,652,43717.21%911.39%70-12.50%3512.90%
Mar 31, 20251373.79%73,635,54347.89%851.61%8224.24%30-26.83%
Dec 31, 202413012.07%49,788,21014.69%731.80%6518.18%4014.29%
Sep 30, 2024116-8.66%43,410,314-0.50%631.54%56-3.45%35-25.53%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.25M2.52%-49.88K
iShares Russell 2000 ETF1.67M1.88%-
Fidelity Select Biotechnology1.34M1.50%-
Fidelity Small Cap Growth987.13K1.11%987.13K
Vanguard Small Cap Index646.02K0.95%1.52K
Vanguard Institutional Extnd Mkt Idx Tr779.02K0.87%-356.52K
Fidelity Small Cap Index695.51K0.78%695.51K
Jupiter Merian Glb Eq AbsRet I USD Acc480.21K0.71%185.87K
Fidelity Small Cap Growth K6492.63K0.55%492.63K
iShares Russell 2000 Growth ETF471.66K0.53%-

Recent Insider Transactions


DateNameRoleActivityValue
Sep 30, 2025Klee Justin B. Co-Chief Executive OfficerSell$3.00K
Sep 30, 2025Klee Justin B. Co-Chief Executive OfficerSell$427.95K
Sep 30, 2025Mazzariello Gina Chief Legal OfficerSell$128.67K
Sep 30, 2025FRATES JAMES M Chief Financial OfficerSell$154.65K
Sep 30, 2025Cohen Joshua B Co-Chief Executive OfficerSell$426.47K

Insider Transactions Trends


DateBuySell
2025 Q3-9
2025 Q2--
2025 Q1114
2024 Q4-1
2024 Q334

AMLX Ownership FAQ


Who Owns Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals shareholders are primarily institutional investors at 122.91%, followed by 7.62% insiders and -30.53% retail investors. The average institutional ownership in Amylyx Pharmaceuticals's industry, Biotech Stocks , is 45.24%, which Amylyx Pharmaceuticals exceeds.

Who owns the most shares of Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals’s largest shareholders are Fmr (11.38M shares, 12.77%), Perceptive advisors (8.95M shares, 10.04%), and Blackrock funding, inc. /de (7.14M shares, 8.01%). Together, they hold 30.82% of Amylyx Pharmaceuticals’s total shares outstanding.

Does Blackrock own Amylyx Pharmaceuticals?

Yes, BlackRock owns 3.93% of Amylyx Pharmaceuticals, totaling 2.67M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 5.07M$. In the last quarter, BlackRock decreased its holdings by -1.805M shares, a -40.34% change.

Who is Amylyx Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Saturn v capital management is Amylyx Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 13.72% of its assets in 4.6M Amylyx Pharmaceuticals shares, valued at 62.58M$.

Who is the top mutual fund holder of Amylyx Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Amylyx Pharmaceuticals shares, with 2.52% of its total shares outstanding invested in 2.25M Amylyx Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools